SEARCH

SEARCH BY CITATION

References

  • 1
    Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet. 1999; 353: 14-17.
  • 2
    McDermott DF,Regan MM,Clark JI, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 2005; 23: 133-141.
  • 3
    Yang JC,Haworth L,Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003; 349: 427-434.
  • 4
    Escudier B,Eisen T,Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007; 356: 125-134.
  • 5
    Motzer RJ,Hutson TE,Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356: 115-124.
  • 6
    Ljungberg B,Alamdari FI,Rasmuson T,Roos G. Follow-up guidelines for nonmetastatic renal cell carcinoma based on the occurrence of metastases after radical nephrectomy. BJU Int. 1999; 84: 405-411.
  • 7
    Therasse P,Arbuck SG,Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205-216.
  • 8
    Sivaramakrishna B,Gupta NP,Wadhwa P, et al. Pattern of metastases in renal cell carcinoma: a single institution study. Indian J Cancer. 2005; 42: 173-177.
  • 9
    Lee DS,White DE,Hurst R,Rosenberg SA,Yang JC. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2 -based immunotherapy. Cancer J Sci Am. 1998; 4: 86-93.
  • 10
    Haas NB,Uzzo RG. Tyrosine kinase inhibitors and anti-angiogenic therapies in kidney cancer. Curr Treat Options Oncol. 2007; 8: 211-226.
  • 11
    Hahn O,Stadler W. Sorafenib. Curr Opin Oncol. 2006; 18: 615-621.
  • 12
    Jacobsohn KM,Wood CG. Adjuvant therapy for renal cell carcinoma. Semin Oncol. 2006; 33: 576-582.
  • 13
    Shuch B,Riggs SB,Larochelle JC, et al. Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm. BJU Int. 2008; 102: 692-696.
  • 14
    Benjamin RS,Choi H,Macapinlac HA, et al. We should desist using RECIST, at least in GIST. J Clin Oncol. 2007; 25: 1760-1764.
  • 15
    Gollob JA,Bonomi P. Historic evidence and future directions in clinical trial therapy of solid tumors. Oncology (Williston Park). 2006; 20: 10-18.
  • 16
    Tuma RS. Sometimes size doesn't matter: reevaluating RECIST and tumor response rate endpoints. J Natl Cancer Inst. 2006; 98: 1272-1274.
  • 17
    Choi H,Charnsangavej C,Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007; 25: 1753-1759.